CompletedNCT02593643
Ketamine for Suicidal Thoughts in Depression and Bipolarity
About this title
Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.
Read the official source — NCT02593643Medication studyAges 18–65Canada
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Study information
Study start dateJanuary 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 9
- Sponsor
- Sunnybrook Health Sciences Centre
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02593643
- Official title
Show the full official title
A Double-blind Pilot Trial of the Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Sunnybrook Health Sciences Centre.
Did this study involve medication?
Yes. The study involved medication, including ketamine and Midazolam.
Who was this study for?
Listed age limits: 18 years to 65 years.
